Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers

Lhuillier, C., Vanpouille‐Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 63

Delivery of 5′-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy

Jacobson, M. E., Wang-Bishop, L., Becker, K. W., & Wilson, J. T. (2018) · Biomaterials Science · doi:10.1039/c8bm01064a · Cited by 62

Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy

Lee, A. K., Pan, D., Bao, X., Hu, M., Li, F., & Li, C. (2020) · Radiation Research · doi:10.1667/rade-20-00013 · Cited by 69

Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex–mediated STAT1 downregulation

Zhan, X., Guo, S., Li, Y., Ran, H., Huang, H., Mi, L., Wu, J., Wang, X., Xiao, D., Chen, L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191340 · Cited by 61

Targeting STING for cancer immunotherapy: From mechanisms to translation

Huang, R., Ning, Q., Zhao, J., Zhao, X., Zeng, L., Yi, Y., & Tang, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109304 · Cited by 64

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Cauwels, A., Lint, S. V., Garcin, G., Bultinck, J., Paul, F., Gerlo, S., der Heyden, J. V., Bordat, Y., Catteeuw, D., Cauwer, L. D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398876 · Cited by 63

RNA vaccines for cancer: Principles to practice

Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 64

HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer

Rose, R., Lamers, S. L., Nolan, D. J., Maidji, E., Faria, N. R., Pybus, O. G., Dollar, J. J., Maruniak, S. A., McAvoy, A. C., Salemi, M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00684-16 · Cited by 61

Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma

Bu, Y., Liu, F., Jia, Q., & Yu, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165681 · Cited by 62

Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

Mohammad, G. R. K. S., Ghahremanloo, A., Soltani, A., Fathi, E., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29491 · Cited by 60

ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer

Somerville, T. D. D., Xu, Y., Wu, X., Maia-Silva, D., Hur, S. K., de Almeida, L. M. N., Preall, J. B., Koo, P. K., & Vakoc, C. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921484117 · Cited by 60

Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity

Bao, P., Zheng, Z., Ye, J., & Zhang, X. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c03996 · Cited by 59

Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Vacchelli, E., Enot, D. P., Pietrocola, F., Zitvogel, L., & Kroemer, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0294 · Cited by 61

Regulation of cancer‐immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy

Yang, J., & Zhang, C. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1612 · Cited by 59

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC

Li, K., Gong, Y., Qiu, D., Tang, H., Zhang, J., Yuan, Z., Huang, Y., Qin, Y., Ye, L., & Yang, Y. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004006 · Cited by 58

Tyrosine kinase 2 – Surveillant of tumours and bona fide oncogene

Leitner, N. R., Witalisz‐Siepracka, A., Strobl, B., & Müller, M. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.10.015 · Cited by 59

Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist

Nuhn, L., Hoecke, L. V., Deswarte, K., Schepens, B., Li, Y., Lambrecht, B. N., Koker, S. D., David, S. A., Saelens, X., & Geest, B. G. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.026 · Cited by 58

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Staniszewska, A. D., Armenia, J., King, M. A., Michaloglou, C., Reddy, A., Singh, M., Martin, M. S., Prickett, L. B., Wilson, Z., Proia, T. A., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083755 · Cited by 59

Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics

Zhong, F., Lin, Y., Zhao, L., Yang, C., Ye, Y., & Shen, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02292-0 · Cited by 58

Post-nano strategies for drug delivery: multistage porous silicon microvectors

Venuta, A., Wolfram, J., Shen, H., & Mauro Ferrari, B. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01978a · Cited by 57

Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment

Newby, B. N., & Mathews, C. E. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00232 · Cited by 57

NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2

Xu, P., Ye, S., Li, K., Huang, M., Wang, Q., Zeng, S., Chen, X., Gao, W., Chen, J., Zhang, Q., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1448-9 · Cited by 57

A Dual Role of Type I Interferons in Antitumor Immunity

Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 62

AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer

Ma, Z., Li, Z., Mao, Y., Ye, J., Liu, Z., Wang, Y., Wei, C., Cui, J., Liu, Z., & Liang, X. (2023) · Nature Communications · doi:10.1038/s41467-023-41218-5 · Cited by 57

Rupestonic acid derivative YZH-106 suppresses influenza virus replication by activation of heme oxygenase-1-mediated interferon response

Ma, L., Wang, H., Wu, P., Hu, J., Yin, J., Wu, S., Ge, M., Sun, W.-F., Zhao, J., Aisa, H. A., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.021 · Cited by 57

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 56

Trial Watch—Immunostimulation with cytokines in cancer therapy

Vacchelli, E., Aranda, F., Bloy, N., Buqué, A., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115942 · Cited by 60

Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma

Zhu, C., Zou, C., Guan, G., Guo, Q., Yan, Z., Liu, T., Shen, S., Xu, X., Chen, C., Lin, Z., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1621677 · Cited by 55

IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer

Ka, N., Lim, G. Y., Hwang, S., Kim, S.-S., & Lee, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110138 · Cited by 61

Interferon‑α and its effects on cancer cell apoptosis (Review)

Shi, W., Yao, X., Fu, Y., & Wang, Y. (2022) · Oncology Letters · doi:10.3892/ol.2022.13355 · Cited by 55

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

Minnar, C. M., Chariou, P. L., Horn, L. A., Hicks, K. C., Palena, C., Schlom, J., & Gameiro, S. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004561 · Cited by 56

The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration

Van Hoecke, L., Roose, K., Ballegeer, M., Zhong, Z., Sanders, N. N., De Koker, S., Saelens, X., & Van Lint, S. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.09.004 · Cited by 55

Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors

Zhang, H., Yu, P., Tomar, V. S., Chen, X., Atherton, M. J., Lu, Z. F., Zhang, H.-G., Li, S., Ortiz, A., Gui, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00383-0 · Cited by 57

Design, synthesis, molecular docking and DFT computational insight on the structure of Piperazine sulfynol derivatives as a new antibacterial contender against superbugs MRSA

Prasad, H. S. N., Ananda, A. P., Lohith, T. N., Prabhuprasad, P., Jayanth, H. S., Krishnamurthy, N. B., Sridhar, M. A., Mallesha, L., & Mallu, P. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131333 · Cited by 54

Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy

Dong, X., Pan, P., Ye, J., Zhang, Q., & Zhang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121763 · Cited by 58

Immunomodulatory activity of manganese dioxide nanoparticles: Promising for novel vaccines and immunotherapeutics

Huang, Y., Ruan, Y., Ma, Y., Chen, D., Zhang, T., Fan, S., Lin, W., Huang, Y., Lü, H., Xu, J.-F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128840 · Cited by 55

Virus‐Like Particle‐Induced cGAS‐STING Activation and AIM2 Inflammasome‐Mediated Pyroptosis for Robust Cancer Immunotherapy

Xu, X., Fan, H., Yang, Y., Yao, S., Yu, W., Guo, Z., & Tan, W. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202303010 · Cited by 54

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC

Li, A., Wang, Y., Yu, Z., Tan, Z., He, L., Fu, S., Shi, M., Du, W., Luo, L., Li, Z., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.020 · Cited by 57

Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway

Ding, L., Qian, J., Yu, X., Wu, Q., Mao, J., Liu, X., Wang, Y., Guo, D., Su, R., Xie, H., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216568 · Cited by 54

The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity

Lim, J. K., Rodriguez, R., Williams, K., Silva, J., Gutierrez, A. G., Tyler, P. M., Baharom, F., Sun, T., Lin, E., Martin, S. E., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1078 · Cited by 55

Single-cell RNA sequencing of immune cells in gastric cancer patients

Fu, K., Hui, B., Wang, Q., Chen, L., Shi, W., Zhang, Z., Rong, D., Zhang, B., Tian, Z., Tang, W., et al. (2020) · Aging · doi:10.18632/aging.102774 · Cited by 55

Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways

Kumari, P., Saha, I., Narayanan, A., Narayanan, S., Takaoka, A., Kumar, N. S., Tailor, P. B., & Kumar, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.461 · Cited by 54

Dietary quercetin potentiates the antiproliferative effect of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase

Igbe, I., Shen, X., Jiao, W., Qiang, Z., Deng, T., Li, S., Liu, W., Liu, H.-W., Zhang, G., & Wang, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22556 · Cited by 53

Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection

Macal, M., Jo, Y., Dallari, S., Chang, A. Y., Dai, J., Swaminathan, S., Wehrens, E. J., Fitzgerald-Bocarsly, P. A., & Zúñiga, E. I. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.020 · Cited by 53

Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity

Tsai, K. K., Huang, S., Northey, J. J., Liao, W., Hsu, C., Cheng, L., Werner, M. E., Chuu, C., Chatterjee, C., Lakins, J. N., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00375-0 · Cited by 53

Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy

Huang, Z., Huang, S., Song, S., Ding, Y., Zhou, H., Zhang, S., Weng, L., Zhang, Y., Hu, Y., Yuan, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53084-w · Cited by 52

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

Zhao, H., Ning, S., Nolley, R., Scicinski, J. J., Oronsky, B. T., Knox, S. J., & Peehl, D. M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0312-z · Cited by 56

CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma

Silva, L. F. O. E., Fonseca, F. P., de Almeida, O., Mariz, B. A. L. A., Lopes, M., Radhakrishnan, R. A., Sharma, M., Kowalski, L. P., & Vargas, P. A. (2019) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.23177 · Cited by 51

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer

Unal, B., Kuzu, O. F., Jin, Y., Osorio, D., Kildal, W., Pradhan, M., Kung, S. H. Y., Oo, H. Z., Daugaard, M., Vendelbo, M. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53039-1 · Cited by 53

Microbiota-derived metabolites: Key modulators of cancer immunotherapies

Perl, M., Fante, M. A., Herfeld, K., Scherer, J. N., Poeck, H., & Orberg, E. T. (2025) · Med · doi:10.1016/j.medj.2025.100773 · Cited by 57

The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway

Martín-Hijano, L., & Sáinz, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00526 · Cited by 53

Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia

Wedenoja, S., Yoshihara, M., Teder, H., Sariola, H. V., Gissler, M., Katayama, S., Wedenoja, J., Häkkinen, I. M. K., Ezer, S., Linder, N., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102872 · Cited by 51

Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50

Transformable DNA nanocarriers for plasma membrane targeted delivery of cytokine

Sun, W., Ji, W., Hu, Q., Yu, J., Wang, C., Qian, C., Hochu, G. M., & Gu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.011 · Cited by 50

Beyond the Double-Strand Breaks: The Role of DNA Repair Proteins in Cancer Stem-Cell Regulation

Nathansen, J., Meyer, F., Müller, L., Schmitz, M., Borgmann, K., & Dubrovska, A. (2021) · Cancers · doi:10.3390/cancers13194818 · Cited by 51

Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma

Chen, L., Chao Hui, Z. H. O. U., Chen, Q., Shang, J., Liu, Z., Guo, Y., Li, C., Wang, H.-J., Ye, Q., Li, X., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.011 · Cited by 53

Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer

Wang, H., Yao, Z., Kang, K., Zhou, L., Xiu, W., Sun, J., Xie, C., Yu, M., Li, Y., Zhang, Y., et al. (2024) · Med · doi:10.1016/j.medj.2024.06.002 · Cited by 50

The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes

Erasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 52

Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice

Apps, J. R., & Martı́nez-Barberá, J. P. (2016) · Neurosurgical FOCUS · doi:10.3171/2016.8.focus16307 · Cited by 49

RNA sensor LGP2 inhibits TRAF ubiquitin ligase to negatively regulate innate immune signaling

Parisien, J.-P., Lenoir, J. J., Mandhana, R., Rodriguez, K. R., Qian, K., Bruns, A. M., & Horvath, C. M. (2018) · EMBO Reports · doi:10.15252/embr.201745176 · Cited by 52

Thermoresponsive and Protease‐Cleavable Interferon‐Polypeptide Conjugates with Spatiotemporally Programmed Two‐Step Release Kinetics for Tumor Therapy

Wang, Z., Guo, J., Sun, J., Liang, P., Yan, W., Deng, X., & Gao, W. (2019) · Advanced Science · doi:10.1002/advs.201900586 · Cited by 49

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Ioannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., Papazoglou, D., Sutton, L., Rosenquist, R., Amini, R., et al. (2020) · Blood · doi:10.1182/blood.2020006073 · Cited by 49

Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer

Zhu, B., Cai, Y., Zhou, L., Zhao, L., Chen, J., Shan, X., Sun, X., You, Q., Gong, X., Zhang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55904-z · Cited by 48

Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer

Goodman, M. L., Trinca, G. M., Walter, K. R., Papachristou, E. K., D’Santos, C. S., Li, T., Liu, Q., Lai, Z., Chalise, P., Madan, R., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801152 · Cited by 48

Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy

Song, H., Su, Q., Shi, W., Huang, P., Zhang, C., Zhang, C., Liu, Q., & Wang, W. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.01.004 · Cited by 47

cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity

Mekers, V. E., Kho, V. M., Ansems, M., & Adema, G. J. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.07.014 · Cited by 47

Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment

Baharom, F., Hermans, D., Delamarre, L., & Seder, R. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01091-9 · Cited by 47

NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB

Kabacaoğlu, D., Ruess, D. A., Ai, J., & Algül, H. (2019) · Cancers · doi:10.3390/cancers11070937 · Cited by 49

Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Chen, M., Hu, S., Li, Y., Jiang, T., Jin, H., & Feng, L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00347-9 · Cited by 47

Overview of vaccine adjuvants

Wu, Z., & Liu, K. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100103 · Cited by 47

TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy

Hamon, P., de Thoré, M. G., Classe, M., Signolle, N., Liu, W., Bawa, O., Meziani, L., Clémenson, C., Milliat, F., Deutsch, É., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003519 · Cited by 51

Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance

Katopodi, T., Petanidis, S., Charalampidis, C., Chatziprodromidou, I. P., Eskitzis, P., Tsavlis, D., Zarogoulidis, P., Kosmidis, C. S., Matthaios, D., & Porpodis, Κ. (2022) · Cells · doi:10.3390/cells11203183 · Cited by 47

Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells

Walton, R. W., Brown, M. C., Sacco, M. T., & Gromeier, M. (2018) · Journal of Virology · doi:10.1128/jvi.00879-18 · Cited by 46

Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity

Lybaert, L., Vermaelen, K. Y., Geest, B. G. D., & Nuhn, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.009 · Cited by 46

Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes

Hammerl, D., Massink, M. P. G., Smid, M., van Deurzen, C. H. M., Meijers-Heijboer, H. E. J., Waisfisz, Q., Debets, R., & Martens, J. W. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0285 · Cited by 46

Spatial transcriptomics reveals gene expression characteristics in invasive micropapillary carcinoma of the breast

Lv, J., Shi, Q., Han, Y., Li, W., Liu, H., Zhang, J., Niu, C., Gao, G., Fu, Y., Zhi, R., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04380-6 · Cited by 46

ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models

Jin, W. J., Zangl, L. M., Hyun, M., Massoud, E., Schroeder, K., Alexandridis, R. A., & Morris, Z. S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007474 · Cited by 45

Plasmacytoid dendritic cell role in cutaneous malignancies

Saadeh, D., Kurban, M., & Abbas, O. M. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.05.008 · Cited by 46

ATF3 negatively regulates cellular antiviral signaling and autophagy in the absence of type I interferons

Sood, V., Sharma, K. B., Gupta, V., Saha, D., Dhapola, P., Sharma, M., Sen, U., Kitajima, S., Chowdhury, S., Kalia, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08584-9 · Cited by 45

Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon

Graffeo, C. S., Perry, A., Link, M. J., & Daniels, D. J. (2018) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0037-1621738 · Cited by 45

Contribution of annexin A1 to anticancer immunosurveillance

Baracco, E. E., Stoll, G., Endert, P. V., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1647760 · Cited by 46

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma

Tao, H., Jin, C., Zhou, L., Deng, Z., Li, X., Dang, W., Fan, S., Li, B., Ye, F., Lu, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1082 · Cited by 44

Genomic instability as a driver and suppressor of anti-tumor immunity

Requesens, M., Foijer, F., Nijman, H. W., & de Bruyn, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462496 · Cited by 45

Impact of Type I Interferons on Susceptibility to Bacterial Pathogens

Peignier, A., & Parker, D. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.01.007 · Cited by 44

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer

Zheng, X., Liu, Z., Mi, M., Wen, Q., Wu, G., & Zhang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734853 · Cited by 44

The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy

Grass, G. D., Alfonso, J. C. L., Welsh, E. A., Ahmed, K. A., Teer, J. K., Pilon‐Thomas, S., Harrison, L. B., Cleveland, J. L., Mulé, J. J., Eschrich, S. A., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.006 · Cited by 44

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy

Dai, W., Zhang, J., Li, S., He, F., Liu, Q., Gong, J., Yang, Z., Gong, Y. Q., Tang, F., Wang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865964 · Cited by 49

Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING

Wang, L., Luo, R., Onyshchenko, K., Rao, X., Wang, M., Menz, B., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006235 · Cited by 45

Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response

Vulpis, E., Soriani, A., Cerboni, C., Santoni, A., & Zingoni, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030611 · Cited by 43

Human Tumor-Infiltrating Dendritic Cells: From In Situ Visualization to High-Dimensional Analyses

Hubert, M., Gobbini, É., Bendriss‐Vermare, N., Caux, C., & Valladeau‐Guilemond, J. (2019) · Cancers · doi:10.3390/cancers11081082 · Cited by 45

The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer

Kim, H. Y., Kim, T. H., Yoon, H. K., & Lee, A. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e41 · Cited by 43

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation

Carlsen, L., & El‐Deiry, W. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.998388 · Cited by 42

Role of Defensins in Tumor Biology

Adyns, L., Proost, P., & Struyf, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065268 · Cited by 42

Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

Achard, C., Guillerme, J.-B., Bruni, D., Boisgerault, N., Combredet, C., Tangy, F., Jouvenet, N., Grégoire, M., & Fonteneau, J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261240 · Cited by 42

Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses

Dallari, S., Macal, M., Loureiro, M. E., Jo, Y., Swanson, L., Hesser, C. R., Ghosh, P., & Zúñiga, E. I. (2017) · Nature Communications · doi:10.1038/ncomms14830 · Cited by 44

Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin

Hiller, B., Hoppe, A., Haase, C., Hiller, C., Schubert, N., Müller, W., Reijns, M. A. M., Jackson, A. P., Kunkel, T. A., Wenzel, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1099 · Cited by 43

Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity

Zhang, F., Manna, S., Pop, L. M., Chen, Z. J., Fu, Y., & Hannan, R. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.009 · Cited by 44

Degradation Products of Complex Arabinoxylans by Bacteroides intestinalis Enhance the Host Immune Response

Yasuma, T., Toda, M., Abdel-Hamid, A. M., D’Alessandro‐Gabazza, C. N., Kobayashi, T., Nishihama, K., D’Alessandro, V. F., Pereira, G. V., Mackie, R. I., Gabazza, E. C., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9061126 · Cited by 42

Histone H2A.Z Suppression of Interferon-Stimulated Transcription and Antiviral Immunity Is Modulated by GCN5 and BRD2

Au-Yeung, N., & Horvath, C. M. (2018) · iScience · doi:10.1016/j.isci.2018.07.013 · Cited by 44

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147